In terms of early detection, the COMET‐LR and the combination model reached a remarkable sensitivity of 82.4% and 85.3% in stage I cancer cases, which outperformed AFP (32.4%) and PIVKA‐II alone (55.9%, Figure 3F). Here, AFP is linked to cancer.